Primaquine, an 8-amino-6-methoxyquinoline antimalarial agent, was subjected to metabolic studies with microorganisms. Streptomyces rimosus converted primaquine to the previously reported N-acetyl derivative. Continued incubation of S. rimosus resulted in the formation of a minor dimeric metabolite. The structure of the minor dimeric metabolite was proposed based primarily on its spectral data ('H and 13C nuclear magnetic resonance spectra and mass spectrum). The proposed structure of the metabolite was confirmed by synthesis of the dimer by treatment of primaquine-N-acetate with potassium ferricyanide in a biphasic chloroform-aqueous sodium bicarbonate system with a phase-transfer catalyst. Since (+)-primaquine was used for both the microbial transformation and synthesis, a diastereomeric mixture of symmetrical dimers was formed in each case. The metabolite sample was identical to the synthetic sample, as shown by direct comparison (thin-layer chromatography, co-thin-layer chromatography, high-pressure liquid chromatography, co-high-pressure liquid chromatography, 1H nuclear magnetic resonance spectra, and mass spectrum).
Primaquine (I; Fig. 1 ) is an 8-amino-6-methoxyquinoline derivative which is an important antimalarial agent since it is useful in the radical cure of vivax malaria (7) . One of the major drawbacks to the use of primaquine is its low chemotherapeutic index. It was speculated for years that the toxicity of primaquine, manifested primarily as hemolytic anemia in individuals with a deficiency of glucose-6-phosphate dehydrogenase (2), was due not to primaquine itself but to a metabolite(s) of primaquine. Efforts to produce and identify possible mammalian metabolites of primaquine by studying its microbial metabolism have previously resulted in the isolation and identification of three metabolites. The carboxylic acid metabolite (II; Fig. 1 ) was identified as the major metabolite of primaquine produced by the fungus Aspergillusflavus (4) . The N-acetate derivative (III; Fig. 1 ) was found to be the major metabolite of primaquine produced by species of Streptomyces (4, 5) and Candida (3) . Subsequently, the carboxylic acid metabolite was also identified as the major metabolite of primaquine in the plasma of rats ( Res., in press).
It would appear, then, that other metabolic transformations would occur only after alteration of the terminal amino group. Previous studies on the metabolism of the carboxylic acid metabolite have shown that it is converted to the amnide (IV; Fig. 1 ) by Streptomyces rimosus (6) . Extension of the incubation period of the N-acetate-producing Candida tropicalis resulted in the production of one additional minor dimeric metabolite (V; Fig. 1 
) (3).
This report describes the production, isolation, and identification of a second minor dimeric metabolite (VI; Fig. 1 Synthesis of metabolite VI from primaquine-N-acetate (III). To a stirred suspension of chloroform (100 ml) and potassium ferricyanide (40 g) dissolved in 5% aqueous sodium bicarbonate (200 ml) was added a solution of (+)-primaquine-N-acetate (III; 2.5 g, 8.3 mM) (4) in 200 ml of chloroform, followed by the addition of 0.1 ml of a phase-transfer catalyst (Adogen 464; Aldrich). The reaction mixture was stirred at room temperature for 36 h. The chloroform layer was separated, and the aqueous layer was extracted with chloroform. The combined chloroform layers were washed with water, dried (Na2SO4), and evaporated in vacuo (40°C) to leave a dark-yellow oily residue. The residue was flashchromatographed over alumina (for dry-column chromatography, activity 111/20 mm; Woelm TSC) with increasing percentages of ethyl acetate in hexane as the eluent. Elution with 10% ethyl acetate in hexane afforded the N-acetate derivative (III; 708 mg). Continued elution with 20% ethyl acetate in hexane yielded the coupled product (metabolite VI; 792 mg, 16% yield) as an amorphous solid. amino group of the 8-amino alkyl side chain. Since it appeared that alteration of the primary amino group occurred before metabolic transformation at other positions on the molecule could be accomplished, we investigated the effect of extending the incubation period of microorganisms which produce the N-acetate derivative (III) as the major metabolite. One such study led to the production, isolation, and identification of a novel dimeric metabolite (V) of primaquine produced by C. tropicalis (3) . In a similar study it has been found that S. rimosus, upon continued incubation after the formation of the N-acetate derivative, also produced an additional minor novel metabolite.
The biotransformation of primaquine by S. rimosus was accomplished by the usual two-stage fermentation procedure (4). Thin-layer chromatographic analyses of the ethyl acetate extracts of the culture broth of primaquine-fed S. rimosus cultures showed the presence of the previously known primaquine-N-acetate and one additional minor novel metabolite at an Rf of 0.38. The novel minor metabolite was isolated after preparative scale fermentation of S. rimosus with (+)-primaquine diphosphate. The aqueous culture broth was extracted with ethyl acetate, and the ethyl acetate extract was initially purified by flash-chromatography over alumina which yielded the previously known N-acetate derivative (4) and a second fraction which contained the crude novel metabolite. Further purification by preparativelayer chromatography afforded the pure metabolite which was characterized primarily on the basis of a comparison of its spectral data with that of the N-acetate derivative (4) .
Mass spectral analysis of the metabolite showed peaks at mlz (relative abundance) 600 (M+, 100%), 500 (73%), and 200 (52%). Field desorption mass spectral analysis also showed the parent ion at mlz 600 (90%), which represented essentially a doubling of the molecular weight as compared with the N-acetate derivative (molecular weight, 301).
The 13C NMR spectra of the metabolite and primaquine-N-acetate were very similar (Table 1 ). There were essentially no differences in the aliphatic portions of the 13C NMR spectra of the metabolite and primaquine-N-acetate. There were also no significant differences in chemical shifts and multiplicities of the downfield aromatic signals and the carbonyl signal of the two spectra. The major differences between the two spectra were the chemical shifts and multiplicities of the upfield aromatic signals for C-5 and C-7 (Table 1 ). In the single-frequency off-resonance decoupled spectrum of the N-acetate derivative, C-S and C-7 resonate as doublets at 91.9 and 96.9 ppm, respectively. However, in the single-frequency off-resonance decoupled spectrum of the metabolite, one of the two upfield aromatic signals appeared as a singlet at 104.3 ppm, whereas the other appeared as a doublet at 93.4 ppm, indicating that substitution at either C-S or C-7 had occurred.
Substitution at C-S or C-7 was further supported by the 'H NMR spectrum of the metabolite, which was also very similar to that of the N-acetate derivative ( Table 2 ). The aliphatic regions of the spectra were essentially the same. However, H-4 in the metabolite was considerably upfield relative to its position in the N-acetate derivative (Table 2) . This suggests substitution at C-S since it seems improbable that substitution at C-7 would result in a significant anisotropic effect on H-4.
The fact that the molecular weight of the metabolite was twice that of the N-acetate derivative, coupled with the simplicity of the 13C and 1H NMR spectra, suggests that the metabolite was composed of two primaquine-N-acetate units linked symmetrically at the 5,5" positions (300 + 300 = 600), as shown by structure VI (Fig. 1) .
Confirmation of the substitution at C-5 was obtained from an analysis of the proton-coupled '3C NMR spectrum of the metabolite. The signal for the unsubstituted carbon at 93.4 ppm appeared as a somewhat broadened doublet (1JC-H = 153.3 Hz) and the signal for the substituted carbon at 104.3 ppm appeared as a triplet (3JC-H = 3.9 Hz). Upon addition of D20 to the sample, the signal at 93.4 ppm sharpened significantly due to the loss of long-range coupling (broadening) to the amine proton, an effect previously observed in primaquine and its derivatives and which has served as an aid in the assignment of the C-7 signal. The pattern for the substituted carbon at 104.3 ppm remained unchanged, as would be expected for C-5 substitution (if C-7 was substituted, the signal at 93.4 ppm would be expected to appear as a double doublet and be unaffected by addition of D20). These patterns are consistent only with the assignment of the triplet signal for the substituted carbon at 104.3 ppm to C-5 (equal three-bond couplings to H-4 and H-7) and the doublet for the unsubstituted carbon at 93.4 ppm to C-7 (one-bond coupling to H-7).
The proposed structure of the metabolite was confirmed by its synthesis from (+)-primaquine-N-acetate. The Nacetate derivative, which was prepared from (±)-primaquine by the standard acetylation procedure (4), was treated with potassium ferricyanide in a biphasic aqueous sodium bicarbonate-chloroform system with a phase-transfer catalyst. The 5,5"-linked dimer was obtained in a 16% yield. Direct comparison of the metabolite with the synthetic product VI showed the two to be identical (thin-layer chromatography, co-thin-layer chromatography, HPLC, co-HPLC, 1H NMR spectra, and mass spectra).
Since primaquine contains one asymmetric center in its side chain and since (±)-primaquine was utilized as starting material for both the microbial transformation and the synthesis, one would expect the dimeric product to consist of a mixture of diastereomers. In addition, the dimeric product actually represents a di-ortho-substituted biphenyl-like system which is capable of asymmetry due to restricted rotation. As a result of the presence of three chiral centers and the symmetry of the molecule, one would expect the dimeric product from (±)-primaquine to consist of a mixture of three enantiomeric pairs of diastereomers. Since the enantiomeric pairs have a diastereomeric relationship, they were separable by HPLC with a reversed-phase column with a methanolphosphate buffer mobile phase. In both cases, three peaks in a 1:2:1 ratio, designated compounds VIa, VIb, and VIc, respectively, were observed at retention volumes of 5.7, 6.9, and 8.6 ml, respectively. With a preparative reversed-phase column, the three enantiomeric pairs of diastereomers were separated from each other and shown by 1H NMR and highresolution mass spectral analyses to be isomeric. The 1H NMR (CDCl3) spectrum of each of the isomers was identical to the others and to the original isomeric mixture.
Based on studies in microorganisms (4, 6) and mammals (1), it appears that metabolic transformations involving the aromatic nucleus of primaquine do not occur until the terminal primary amine group is altered in some way. In addition, the formation of metabolite V (Fig. 1) by C. tropicalis (3) and metabolite VI by S. rimosus underscore the apparent reactivity of the 5-position of the primaquine nucleus (5) . Although the formation of dimeric metabolites of primaquine has not yet been demonstrated in mammalian systems, the alkylation of the 5-position in biological systems may be a significant factor in the mechanism of action or toxicity of primaquine or both.
